Europe — EMA
Naratriptan Teva (Naratriptan Hydrochloride)
GNH USA supplies Naratriptan Teva (Naratriptan), a Triptan for acute migraine treatment. Request a quote for global supply.
Request sourcing
What is Naratriptan Hydrochloride?
Naratriptan, the active ingredient in Naratriptan Teva, is a Triptan (5-HT1B/1D receptor agonist) presented as an oral tablet for oral use. It is used for the acute treatment of migraine attacks in adults. GNH USA supplies Naratriptan Teva as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.
What is Naratriptan Hydrochloride used for?
Naratriptan belongs to the triptan class and is used to treat migraine attacks by targeting serotonin pathways.
Migraine: provides rapid relief of acute migraine headache and associated symptoms. Migraine with aura: reduces pain and other migraine‑related manifestations during an attack.
What are the side effects of Naratriptan Hydrochloride?
Common Side Effects: - Nausea: mild to moderate upset stomach. - Dizziness: transient light‑headedness. - Fatigue: feeling unusually tired. - Dry mouth: reduced salivation.
Serious or Rare Side Effects: - Chest pain: possible cardiac ischemia. - Severe hypertension: marked increase in blood pressure. - Serotonin syndrome: agitation, hyperthermia, muscle rigidity. - Allergic reaction: rash, swelling, or anaphylaxis.
What precautions apply to Naratriptan Hydrochloride?
Precautions should be observed before prescribing Naratriptan. - Cardiovascular assessment: evaluate for coronary artery disease or uncontrolled hypertension. - History of ischemic heart disease: avoid use due to risk of vasospasm. - Concomitant serotonergic agents: monitor for serotonin syndrome. - Pregnancy and lactation: safety not established; weigh risks and benefits. - Storage: Store at room temperature: keep in the original pack, protect from moisture.
What does Naratriptan Hydrochloride interact with?
Naratriptan may interact with several drug classes.
Major Interactions (Avoid): - MAO inhibitors: risk of severe hypertension. - SSRIs, SNRIs, or other serotonergic drugs: potential serotonin syndrome. - Ergot derivatives: additive vasoconstriction.
Moderate Interactions (Monitor Closely): - Antihypertensives: possible additive blood pressure lowering. - Dihydropyridine calcium channel blockers: may enhance vasoconstrictive effect. - Oral contraceptives: monitor for increased migraine frequency.



